Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 clinical trial to evaluate the tolerability of a combination therapy of SyB
C-1101 (rigosertib sodium) and Azacytidine and to determine the recommended dose of SyB
C-1101for Phase 2 trial in patients with myelodysplastic syndrome.